- Home
- LIEN vs AVIR Comparison
LIEN vs AVIR Comparison
Compare LIEN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- AVIR
- Stock Information
- Founded
- LIEN 2021
- AVIR 2012
- Country
- LIEN United States
- AVIR United States
- Employees
- LIEN N/A
- AVIR N/A
- Industry
- LIEN
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LIEN
- AVIR Health Care
- Exchange
- LIEN NYSE
- AVIR Nasdaq
- Market Cap
- LIEN 234.6M
- AVIR 273.0M
- IPO Year
- LIEN 2022
- AVIR 2020
- Fundamental
- Price
- LIEN $10.55
- AVIR $3.60
- Analyst Decision
- LIEN Buy
- AVIR Hold
- Analyst Count
- LIEN 2
- AVIR 1
- Target Price
- LIEN N/A
- AVIR $6.00
- AVG Volume (30 Days)
- LIEN 59.4K
- AVIR 393.3K
- Earning Date
- LIEN 08-07-2025
- AVIR 08-06-2025
- Dividend Yield
- LIEN 12.89%
- AVIR N/A
- EPS Growth
- LIEN 30.25
- AVIR N/A
- EPS
- LIEN 1.15
- AVIR N/A
- Revenue
- LIEN $30,828,508.00
- AVIR N/A
- Revenue This Year
- LIEN $154.46
- AVIR N/A
- Revenue Next Year
- LIEN $10.64
- AVIR N/A
- P/E Ratio
- LIEN $9.15
- AVIR N/A
- Revenue Growth
- LIEN 151.96
- AVIR N/A
- 52 Week Low
- LIEN $9.70
- AVIR $2.46
- 52 Week High
- LIEN $13.38
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- AVIR 67.82
- Support Level
- LIEN N/A
- AVIR $3.66
- Resistance Level
- LIEN N/A
- AVIR $3.83
- Average True Range (ATR)
- LIEN 0.00
- AVIR 0.13
- MACD
- LIEN 0.00
- AVIR 0.00
- Stochastic Oscillator
- LIEN 0.00
- AVIR 85.11
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).